Background: Treatment options for wild-type BRAF melanoma patients remain limited. Selumetinib, a MEK 1/2 inhibitor, suppresses pERK levels independent of BRAF and NRAS mutation status, and combination with docetaxel has demonstrated synergy in xenograft models. The aim of this study was to assess the efficacy and safety of selumetinib plus docetaxel as first-line treatment in patients with wild-type BRAF advanced melanoma.
introduction
Melanoma has a median overall survival (OS) of around 8 months from diagnosis of stage 4 disease, and in 2008 was responsible for about 46 000 deaths worldwide [1] . Cytotoxic agents produce responses in a minority (5%-20%) of patients, with combination regimes showing no benefit in OS over monotherapy [2] . Recently, four new drugs have been licensed for this indication: ipilimumab [a cytotoxic T-lymphocyte antigen 4 (CTLA-4) inhibitor] and, for patients with BRAF V600-mutated melanoma, the BRAF inhibitors vemurafenib and dabrafenib and the MEK inhibitor trametinib. Another approach, targeting programmed death 1 (PD-1) or its ligand, has shown promising results and is currently in Phase III trials [3] . Combinations of these novel therapies are also being investigated, with promising results combining BRAF and MEK inhibitors in BRAF-mutated melanoma [4] and combining ipilimumab and PD-1 antibodies [5] .
ERK1/2 is constitutively active in melanoma cells regardless of mutation status, and plays key roles in cell cycle entry, invasion and angiogenesis [6] . BRAF inhibitors have transformed the treatment of melanoma for patients whose tumours harbour V600 mutations [7, 8] . However, for patients without BRAF mutations, treatment options remain more limited, with ipilimumab currently only licensed to be used second line in some territories.
Selumetinib (AZD6244; ARRY-142886) is a highly selective non-ATP-competitive inhibitor of MEK1/2, suppressing pERK levels in melanoma independent of BRAF and NRAS mutation status [9] . Despite good target inhibition in tumour [10] , the clinical activity of selumetinib monotherapy was disappointing [11] . However, selumetinib plus dacarbazine has shown better progression-free survival (PFS) than dacarbazine alone in V600 mutant melanoma [12] . Results from pre-clinical models suggest that selumetinib monotherapy is cytostatic, but cytotoxic when combined with the anti-mitotic agent docetaxel [9] . In melanoma, docetaxel monotherapy produces response rates of 6%-17%, in line with other cytotoxic agents [13] . Docetaxel induces mitochondrial-dependent apoptosis via activation of Bax [14] . Activation of ERK1/2 results in degradation of Bim and phosphorylation of Bad, inhibiting apoptosis [15] . Taxane resistance can therefore occur as a result of constitutive activation of the Ras-Raf-MEK-ERK axis. Selumetinib and docetaxel have demonstrated synergy in a variety of xenograft models [9, 16] . The combination has been found to be tolerable in a phase I study [17] and has shown promising efficacy in previously treated patients with KRAS mutant advanced non-smallcell lung cancer (NSCLC) [18] .
The aim of this study was to assess the efficacy and safety of selumetinib combined with docetaxel as first-line treatment in patients with wild-type BRAF advanced melanoma.
methods study design and patients
This randomized, double-blind, placebo-controlled, multicentre phase II trial (NCT01256359) was conducted at 18 hospitals across the UK under the auspices of the National Cancer Research Institute Melanoma Clinical Study Group. Participants were eligible if aged 16 years or older, with unresectable stage 3 or 4 BRAF wild-type melanoma, ECOG performance status 0 or 1 and adequate bone marrow, renal and liver function. Patients were ineligible if they had lactate dehydrogenase (LDH) more than twice the upper limit of normal (ULN) or had previously received any chemotherapy for metastatic melanoma or an EGFR, Raf or MEK inhibitor.
All patients provided written informed consent, and the study was conducted in accordance with the UK Clinical Trials Regulations and the ICH guidelines of Good Clinical Practice. The protocol was approved by an independent Research Ethics Committee and by review boards at each study site. 
randomization and masking

end points
The primary end point was PFS, defined as time from date of randomization to the date of progression or date of death from any cause, whichever was first. Patients without an event were censored at the time of their latest assessment. Secondary end points included OS, defined as time from date of randomization to date of death ( patients without an event were censored at date of last visit), objective response rate (ORR), [defined as the best overall response for each patient as a proportion of patients achieving complete response (CR) or partial response (PR)], proportion of patients alive and progression free at 6 months (APF6), as estimated from the Kaplan-Meier plots, and safety and tolerability.
assessments
Tumour response was based on investigator assessment of target and nontarget lesions using computed tomography (CT) or magnetic resonance imaging (MRI) at baseline, weeks 9 and 18 after randomization and every 3 months thereafter. Investigators used a modified Response Evaluation Criteria in Solid Tumours (based on RECIST version 1.0, but with the exception that lymph nodes must be >15 mm in short axis dimension to be considered measurable disease, in keeping with previously published trials of selumetinib [12] ) to establish PFS, ORR and APF6. Confirmation CT scans 4 weeks after a scan showing PR or CR were not required in this protocol. Adverse events (AEs) were graded according to NCI CTCAE version 4.03. All patients receiving any study medications were included in the safety analyses.
statistical analysis
We planned to conduct the primary PFS analysis after at least 58 events (80% power to detect an HR of 0.57, with a one sided α level of 0.10) with a planned 1 year recruitment period and follow-up of all patients for at least 3 months after last patient randomized. Based on this, 80 patients needed to be randomized (1:1). All patients randomized to treatment were included in the primary analyses. The treatment arms were compared for PFS and OS using Cox regression analysis, adjusting for the stratification variables (M status and Performance Status) and checking for proportionality. The ORR was compared between treatment groups using the χ 2 test. The APF6 was compared between treatment groups using the Kaplan-Meier estimates.
NRAS mutation analysis
Analysis of NRAS mutation status was undertaken retrospectively. All samples were enriched for tumour tissue by macro-dissection. Massively parallel sequencing was carried out using the IonTorrent Personal Genome Machine (LifeTechnology). For samples yielding insufficient DNA pyrosequencing was undertaken. The Kaplan-Meier method was used to obtain results patients Between October 2010 and May 2012, 260 patients were screened, 83 of whom were randomized to receive docetaxel plus selumetinib (n = 41) or docetaxel plus placebo (n = 42) ( Figure 1 ). Baseline characteristics were well balanced between the two treatment arms, apart from the median sum of the target lesions (Table 1) . Four patients (three in the selumetinib group and one in the placebo group) did not receive their allocated treatment and so were excluded from the safety and per-protocol (PP) analyses. Of these, two patients were randomized in error and were replaced, the errors being identified before any study treatment was administered, and two patients were too unwell for treatment on cycle 1 day 1 and so withdrawn from the study. The results as per intention-to-treat analysis are 
efficacy
The primary end point of PFS was analysed when 68 primary events (disease progression or death) had occurred, at which point median follow-up was 13.6 months. Median PFS was 4.23 months [90% confidence interval (CI) 3.63-6.90] in the selumetinib group and 3.93 months (90% CI 2.07-4.16) with placebo, giving a HR (adjusted for M status and performance status) of 0.75 (90% CI 0.50-1.14; P = 0.130) ( Figure 2A ; Table 2 ). With 54 deaths recorded at analysis, median OS was 9.5 months (90% CI 8.47-12.53) in the selumetinib group and 11.37 months (90% CI 8.67-16.03) for placebo, with a HR of 1.15 (90% CI 0.71-1.84; P = 0.318) ( Figure 2B ; Table 2 ). Unconfirmed responses occurred in 32% of the selumetinib group and 14% of the placebo group, a difference that was not statistically significant (P = 0.059, χ 2 test). APF6 rate was 40% (90% CI 27-53) in the selumetinib group and 26% (90% CI 15-38) in the placebo group, giving an estimated difference of 14% (90% CI −3.4 to 31.4; P = 0.187) ( Table 2) .
NRAS mutation status was determined for 60 patients. Analysis did not show any significant impact of NRAS mutation status on PFS (Table 2) . Overall survival was inferior in the NRAS mutant population (HR wild-type:mutated 0.78; 95% CI 0.41-1.53).
safety
The median number of cycles administered was six in the selumetinib group and four in the placebo group, with the median dose of docetaxel administered being 94% (range 69-100) and 100% (range 72-100) of the planned dose, respectively. Fortyfive percent of patients required a dose reduction in docetaxel in the selumetinib group versus 20% in the placebo group.
The most frequently reported AEs were fatigue, diarrhoea and rash (Table 3) . Diarrhoea, rash, mucositis, nausea, peripheral oedema, febrile neutropenia and visual disturbances were more common in the selumetinib group. Peripheral neuropathy and dyspepsia were more common in the placebo group. More serious AEs were reported in the selumetinib group than the placebo group, the most common of which was admission for febrile neutropenia.
discussion
The options for treating wild-type BRAF advanced melanoma remain more limited than for the BRAF-mutated population. In this, the first randomized trial in wild-type BRAF melanoma, the addition of selumetinib to docetaxel chemotherapy has not shown a significant difference in PFS compared with docetaxel alone. Our trial was not designed to provide a definitive assessment of the combination, but to determine whether such a study ought to be carried out. Although docetaxel with selumetinib showed better PFS, ORR and AFP6 compared with docetaxel alone this did not meet our pre-specified criteria for initiating a definitive trial, nor translate into an impact upon OS. Median OS in both arms was in keeping with other studies of chemotherapy in unselected melanoma. These data are unlikely to have been affected by post-protocol use of ipilimumab, which was similar in both arms. a In 17 cases, we were unable to establish the NRAS status because there was insufficient material (n = 6), the sample was unavailable (n = 9) or the patient had withdrawn consent (n = 2).
 The combination of docetaxel and selumetinib can be administered effectively to patients with metastatic melanoma, although the combination is less well tolerated than docetaxel alone. We observed a higher rate of febrile neutropenia for docetaxel plus selumetinib than for docetaxel alone (21% versus 12%), in common with the NSCLC trial by Janne et al. [18] . As febrile neutropenia is not commonly seen with selumetinib monotherapy [11] , it is likely that selumetinib enhances the adverse effect of docetaxel, rather than itself causing neutropenia.
In the NSCLC trial, PFS (HR 0.58; 80% CI 0.42-0.79) favoured the combination arm, although this did not translate into a statistically significant improvement in OS (HR 0.8; 80% CI 0.56-1.14). In BRAF V600E mutant melanoma, selumetinib and dacarbazine has shown an improvement in PFS over chemotherapy alone (HR 0.63; 80% CI 0.47-0.84), although again there was no significant difference in OS (HR 0.93; 80% CI 0.67-1.28) [12] . The median PFS with selumetinib and docetaxel in our trial was inferior to that achieved by selumetinib and dacarbazine in V600 mutant BRAF melanoma (4.2 versus 5.6 months) [12] . It remains to be seen whether other MEK inhibitors might achieve better results, considering trametinib has shown a survival advantage over chemotherapy in BRAFmutated melanoma and has potentially superior pharmacokinetics, including a longer half-life [19] .
During the conduct of this study, external evidence came to light of the role NRAS status might play in melanoma response to MEK inhibitors. A non-randomized phase II study of the MEK inhibitor MEK162 recently reported modest activity in patients with NRAS-mutated melanoma [20] . We conducted a post hoc analysis of NRAS mutation status to assess its impact on treatment outcome. OS was inferior in the mutant NRAS population, in keeping with previous published data [21] . There was no correlation between NRAS status and treatment outcome in either arm, in keeping with previous published data with selumetinib [11] . Our data therefore do not support the use of NRAS mutations to select melanoma patients for selumetinib treatment.
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